Figure 1. Cohort selection
Figure 2. Antithrombotic treatment in patients with atrial fibrillation and CHA$_2$DS$_2$-VASc $\geq$2 by year.

(CHA$_2$DS$_2$-VASc: Congestive heart failure, Hypertension, Age $\geq$75 years [doubled], Diabetes mellitus, previous episodes of Stroke or transient ischemic attack or systemic embolism [doubled], Vascular disease, Age 65 to 74 years, Sex category [female];
(Abbreviations: AF=atrial fibrillation; DOACs=direct oral anticoagulants)
Figure 3. Proportion of antiplatelet monotherapy, warfarin, and direct oral anticoagulants in patients at high risk of stroke and the incidences of outcomes after propensity score matching.

(Abbreviations: DOACs=direct oral anticoagulants; INR=international normalized ratio)